Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma

Blood

Volumn 122, Issue 4, 2013, Pages 499-506

  Matasar, Matthew J ^a,b   Czuczman, Myron S ^c   Rodriguez, Maria Alma ^d   Fennessy, Michael ^e   Shea, Thomas C ^f   Spitzer, Gary ^g   Lossos, Izidore S ^h   Kharfan Dabaja, Mohamed A ⁱ   Joyce, Robin ^j   Fayad, Luis ^d   Henkel, Kristen ^a   Liao, Qiming ^k   Edvardsen, Klaus ^k   Jewell, Roxanne C ^k   Fecteau, Doug ^k   Singh, Rajendra P ^k   Lisby, Steen ^l   Moskowitz, Craig H ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e GLAXOSMITHKLINE   (United Kingdom)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^g Bon Secours St Francis Hospital   (United States)

^h UNIVERSITY OF MIAMI   (United States)

ⁱ H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^j BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^k GLAXOSMITHKLINE   (United States)

^l Genmab   (Denmark)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CD20 ANTIGEN; CISPLATIN; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; IFOSFAMIDE; OFATUMUMAB; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ALLOTRANSPLANTATION; ANEMIA; ANTIGEN EXPRESSION; AREA UNDER THE CURVE; ARTICLE; AUTOTRANSPLANTATION; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; IMMUNOPHENOTYPING; INFUSION RELATED REACTION; INTERNATIONAL PROGNOSTIC INDEX; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STEM CELL MOBILIZATION; THERAPY DELAY; THROMBOCYTOPENIA; TREATMENT RESPONSE; CANCER GRADING; DRUG EFFECT; DRUG RESISTANCE; IMMUNOTHERAPY; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; RECURRENT DISEASE; SURVIVAL; TREATMENT FAILURE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; CYTARABINE; DEXAMETHASONE; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FEMALE; HUMANS; IFOSFAMIDE; IMMUNOTHERAPY; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; NEOPLASM GRADING; RECURRENCE; SURVIVAL ANALYSIS; TREATMENT FAILURE; YOUNG ADULT;

EID: 84886058066     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-12-472027     Document Type: Article

References (29)

1. Sehn LH, Donaldson J, Chhanabhai M., et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005; 23(22): 5027-5033. (Pubitemid 46224009)
2. Komrokji RS, Al Ali NH, Beg MS, et al. Outcome of diffuse large B-Cell lymphoma in the United States has improved over time but racial disparities remain: review of SEER data. Clin Lymphoma Myeloma Leuk. 2011; 11(3): 257-260.
3. Gisselbrecht C, Glass B, Mounier N., et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010; 28(27): 4184-4190.
4. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003; 22(47): 7359-7368.
5. Barth MJ, Hernandez-Ilizaliturri FJ, Mavis C., et al. Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma. Br J Haematol. 2012; 156(4): 490-498.
6. Beum PV, Lindorfer MA, Beurskens F, et al. Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. J Immunol. 2008; 181(1): 822-832.
7. Cheson BD. Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. J Clin Oncol. 2010; 28(21): 3525-3530.
8. Coiffier B, Lepretre S, Pedersen L.M., et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood. 2008; 111(3): 1094-1100. (Pubitemid 351213387)
9. Czuczman MS, Fayad L, Delwail V., et al.; 405 Study Investigators. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood. 2012; 119(16): 3698-3704.
10. Hagenbeek A, Gadeberg O, Johnson P., et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood. 2008; 111(12): 5486-5495.
11. Taylor RP, Beum PV, Pawluczkowycz A.W., Beurskens F., Van de Winkel J, Parren PW. Spinning disk confocal fluorescent microscopy (SDCFM) analyses of complement activation promoted by anti-CD20 mAbs rituximab and ofatumumab (HuMax-CD20). Mol Immunol. 2007; 44(16): 3915-3916.
12. Cheson BD, Pfistner B, Juweid M.E., et al.; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25(5): 579-586. (Pubitemid 350002966)
13. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989; 10(1): 1-10. (Pubitemid 19099520)
14. Hans CP, Weisenburger DD, Greiner T.C., et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004; 103(1): 275-282. (Pubitemid 38029949)
15. Tam CS, Bassett R, Ledesma C., et al. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood. 2009; 113(18): 4144-4152.
16. Vose JM, Bierman PJ, Loberiza F.R., et al. Phase II trial of 131-iodine tositumomab with high-dose chemotherapy and autologous stem cell transplantation for relapsed diffuse large B cell lymphoma. Biol Blood Marrow Transplant. 2013; 19: 123-128.
17. Visani G, Malerba L, Stefani P.M., et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood. 2011; 118(12): 3419-3425.
18. Gisselbrecht C, Schmitz N, Mounier N., et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20+ diffuse large B-cell lymphoma: final analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma. J Clin Oncol. 2012; 30: 4462-4469.
19. Jermann M, Jost LM, Taverna C, et al. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Ann Oncol. 2004; 15(3): 511-516. (Pubitemid 38444559)
20. Kewalramani T, Zelenetz AD, Nimer S.D., et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2004; 103(10): 3684-3688. (Pubitemid 38596282)
21. Mey UJ, Olivieri A, Orlopp K.S., et al. DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: a matched-pair analysis. Leuk Lymphoma. 2006; 47(12): 2558-2566. (Pubitemid 44932646)
22. Vellenga E, van Putten WL, van't Veer MB, et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood. 2008; 111(2): 537-543.
23. Elstrom RL, Andemariam B, Martin P., et al. Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma. Leuk Lymphoma. 2012; 53(8): 1469-1473.
24. Forero-Torres A., Bartlett N, Beaven A., et al. Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma. Leuk Lymphoma. 2013; 54: 277-283.
25. Haioun C, Morschhauser F, Jourdan E., et al. Preliminary results of a phase II study of rituximab (R), gemcitabine (Gem), oxaliplatin (Ox) plus enzastaurin (ENZ) followed by ENZ maintenance as salvage regimen for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) [abstract 8069]. J Clin Oncol. 2010; 28(15s).
26. Thieblemont C, Briere J, Mounier N., et al. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol. 2011; 29(31): 4079-4087.
27. Martín A., Conde E, Arnan M., et al.; Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea (GEL/TAMO Cooperative Group). R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. Haematologica. 2008; 93(12): 1829-1836.
28. El Gnaoui T., Dupuis J, Belhadj K., et al. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol. 2007; 18(8): 1363-1368. (Pubitemid 47305011)
29. Lignon J, Sibon D, Madelaine I., et al. Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2010; 10(4): 262-269.